Coronavirus vaccine | Patent Number 11241493

US 11241493 B2

Application Number17231261

Publication NumberUS 20210379181 A1

Pendency9 months, 29 days

Filled DateApr 15, 2021

Priority DateNov 10, 2020

Publication DateDec 9, 2021

Expiration DateNov 9, 2040

Inventor/ApplicantsHans Wolfgang Grosse
Benjamin Petsch
Susanne Rauch
Benjamin PETSCH
Hans Wolfgang GROssE
Susanne RAUCH

ExaminesCHESTNUT, BARRY A

Art Unit1648

Technology Center1600

Assignments

Law Firm

You must be logged in to view

Attorneys

Module Locked

International

A61P

C07K

C12N

A61K

National

Field of Search

1. A composition comprising a mRNA comprising: (a) at least one coding sequence encoding a SARS-CoV-2 spike protein (S) at least 95% identical to SEQ ID NO: 10 that is a pre-fusion stabilized spike protein (S_stab) comprising a pre-fusion stabilizing K986P and V987P mutation; (b) at least one heterologous untranslated region (UTR); and (c) at least one pharmaceutically acceptable carrier, wherein the mRNA is complexed or associated with lipid nanoparticles (LNP) and wherein the LNP comprises: (i) at least one cationic lipid according to formula III-3: (ii) at least one neutral lipid, comprising 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); (iii) at least one steroid, comprising cholesterol; and (iv) at least one PEG-lipid according to formula IVa: wherein n has a mean value ranging from 30 to 60, wherein (i) to (iv) are in a molar ratio of about 20-60% cationic lipid, 5-25% neutral lipid, 25-55% sterol, and 0.5-15% PEG-lipid.

Patent Claims data is locked.

You must be logged in to view

Module Locked

Empower your practice with Patexia Publication Prosecution IP Module.

Get access to our exclusive rankings and unlock powerful data.

Get in touch with our team or create your account to start exploring a network of over 120K attorneys.